neurocare group

neurocare group operates at the intersection of mental-health services, neuromodulation devices, clinical research, and professional education. Its position differs from a pure-play device manufacturer because it combines an international clinic network with TMS, tES, EEG, neurofeedback, and related training and application support. It also differs from a digital mental-health provider focused primarily on software or remote therapy: the portfolio includes regulated hardware such as Apollo TMS, PowerMAG, and neuronavigation systems, alongside clinical delivery. The available comparison data does not identify validated external competitor companies, so relative market share and peer benchmarking remain limited. Within its stated category, the company’s differentiators are the integration of treatment delivery, technology development, research support, and practitioner training, plus an emphasis on personalized assessment and target engagement. FDA clearances for adolescent depression and OCD, the Mid-Ohio network expansion, and the Saudi Arabian approval broaden its addressable clinical and geographic markets.

neurocare group's growth trajectory shows a shift from a specialist neurotechnology company toward a broader, multi-market mental-health platform. The company raised $17.12 million in April 2024 and $20.07 million in February 2025, bringing disclosed funding to $37.19 million across three rounds, although the 2022 venture round has no reported amount. Expansion has combined acquisitions and network integration: Smart TMS was acquired on Jul 22, 2024, MeJa Psychologie on Jul 28, 2025, and five Mid-Ohio Behavioral Health clinics joined the network through a Jul 15, 2025 arrangement. Product and regulatory milestones provide additional inflection points. FDA clearance for OCD treatment and adolescent major depression in August and September 2025 expanded the use cases for its TMS devices, while the 2026 Saudi approval created another international route to market. The January 2026 NRx Pharmaceuticals collaboration extends the platform into a joint neuroplastic-therapy offering. Hiring also indicates organizational scaling, with a new CFO effective January 2025 and a Chief Platform Officer appointed in July 2025. Public employee-growth data is limited, so the pace of operational expansion cannot be quantified precisely.